News & Views
News & Views
Iksuda to present preliminary analysis of oesophageal cancer data from Phase 1 study of IKS014 at ASCO Gastrointestinal Cancer Symposium
Encouraging anti-tumour activity seen across all dose levels and in various tumour indications Clinical benefit rate of 80% for 10 patients with HER2+ oesophageal cancer who had received prior therapy that included a trastuzumab component in at least one prior treatment
Iksuda to present preliminary analysis of oesophageal cancer data from Phase 1 study of IKS014 at ASCO Gastrointestinal Cancer Symposium
Encouraging anti-tumour activity seen across all dose levels and in various tumour indications Clinical benefit rate of 80% for 10 patients with HER2+ oesophageal cancer who had received prior therapy that included a trastuzumab component in at least one prior treatment
Iksuda presents encouraging IKS014 Phase 1 data at ESMO
New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the study Anti-tumour activity observed across all dose levels and in various tumour indications
Iksuda to present IKS014 Phase 1 data at ESMO
Newcastle, UK, 14 October 2025: Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs), will present new data from its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2) ADC, in patients with advanced HER2+ solid tumours, at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany (17-21 October).
Iksuda Therapeutics receives FDA IND clearance for IKS014
FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore. Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical activity across multiple tumour types
First patient dosed in Phase 1 Trial
Iksuda announces first patient dosed in Phase 1 trial of IKS014
Iksuda enters license agreement with University of Goettingen
Iksuda Therapeutics enters license agreement with University of Goettingen to develop a new generation of antibody drug conjugates